Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process
Conclusion: This study highlights the intricate global landscape of RWD and RWE acceptance in HTA. Recognizing regional nuances, addressing methodological challenges, and promoting collaboration are pivotal, among others, for leveraging RWD and RWE effectively in healthcare decision-making.PMID:38481726 | PMC:PMC10932954 | DOI:10.3389/jpps.2024.12302 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - March 14, 2024 Category: Drugs & Pharmacology Authors: Konstantinos Zisis Elpida Pavi Mary Geitona Kostas Athanasakis Source Type: research

Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process
Conclusion: This study highlights the intricate global landscape of RWD and RWE acceptance in HTA. Recognizing regional nuances, addressing methodological challenges, and promoting collaboration are pivotal, among others, for leveraging RWD and RWE effectively in healthcare decision-making.PMID:38481726 | PMC:PMC10932954 | DOI:10.3389/jpps.2024.12302 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - March 14, 2024 Category: Drugs & Pharmacology Authors: Konstantinos Zisis Elpida Pavi Mary Geitona Kostas Athanasakis Source Type: research

Revolutionizing pharmacokinetics: the dawn of AI-powered analysis
J Pharm Pharm Sci. 2024 Feb 16;27:12671. doi: 10.3389/jpps.2024.12671. eCollection 2024.ABSTRACTThis editorial explores how artificial intelligence (AI) is revolutionizing the science of pharmacokinetics (PK). It discusses the challenges of conventional PK analysis and how AI has transformed this area. It highlights the promise of artificial intelligence (AI) in predicting pharmacokinetic profiles from chemical structures and its application in several aspects of pharmacology, including dosage customization and drug interactions. Additionally, it emphasizes how important ethical issues and openness are to AI applications, ...
Source: J Pharm Pharm Sci - March 4, 2024 Category: Drugs & Pharmacology Authors: Ali Ghayoor Hamed Gilzad Kohan Source Type: research

Revolutionizing pharmacokinetics: the dawn of AI-powered analysis
J Pharm Pharm Sci. 2024 Feb 16;27:12671. doi: 10.3389/jpps.2024.12671. eCollection 2024.ABSTRACTThis editorial explores how artificial intelligence (AI) is revolutionizing the science of pharmacokinetics (PK). It discusses the challenges of conventional PK analysis and how AI has transformed this area. It highlights the promise of artificial intelligence (AI) in predicting pharmacokinetic profiles from chemical structures and its application in several aspects of pharmacology, including dosage customization and drug interactions. Additionally, it emphasizes how important ethical issues and openness are to AI applications, ...
Source: J Pharm Pharm Sci - March 4, 2024 Category: Drugs & Pharmacology Authors: Ali Ghayoor Hamed Gilzad Kohan Source Type: research

Revolutionizing pharmacokinetics: the dawn of AI-powered analysis
J Pharm Pharm Sci. 2024 Feb 16;27:12671. doi: 10.3389/jpps.2024.12671. eCollection 2024.ABSTRACTThis editorial explores how artificial intelligence (AI) is revolutionizing the science of pharmacokinetics (PK). It discusses the challenges of conventional PK analysis and how AI has transformed this area. It highlights the promise of artificial intelligence (AI) in predicting pharmacokinetic profiles from chemical structures and its application in several aspects of pharmacology, including dosage customization and drug interactions. Additionally, it emphasizes how important ethical issues and openness are to AI applications, ...
Source: J Pharm Pharm Sci - March 4, 2024 Category: Drugs & Pharmacology Authors: Ali Ghayoor Hamed Gilzad Kohan Source Type: research

Revolutionizing pharmacokinetics: the dawn of AI-powered analysis
J Pharm Pharm Sci. 2024 Feb 16;27:12671. doi: 10.3389/jpps.2024.12671. eCollection 2024.ABSTRACTThis editorial explores how artificial intelligence (AI) is revolutionizing the science of pharmacokinetics (PK). It discusses the challenges of conventional PK analysis and how AI has transformed this area. It highlights the promise of artificial intelligence (AI) in predicting pharmacokinetic profiles from chemical structures and its application in several aspects of pharmacology, including dosage customization and drug interactions. Additionally, it emphasizes how important ethical issues and openness are to AI applications, ...
Source: J Pharm Pharm Sci - March 4, 2024 Category: Drugs & Pharmacology Authors: Ali Ghayoor Hamed Gilzad Kohan Source Type: research

Revolutionizing pharmacokinetics: the dawn of AI-powered analysis
J Pharm Pharm Sci. 2024 Feb 16;27:12671. doi: 10.3389/jpps.2024.12671. eCollection 2024.ABSTRACTThis editorial explores how artificial intelligence (AI) is revolutionizing the science of pharmacokinetics (PK). It discusses the challenges of conventional PK analysis and how AI has transformed this area. It highlights the promise of artificial intelligence (AI) in predicting pharmacokinetic profiles from chemical structures and its application in several aspects of pharmacology, including dosage customization and drug interactions. Additionally, it emphasizes how important ethical issues and openness are to AI applications, ...
Source: J Pharm Pharm Sci - March 4, 2024 Category: Drugs & Pharmacology Authors: Ali Ghayoor Hamed Gilzad Kohan Source Type: research

Revolutionizing pharmacokinetics: the dawn of AI-powered analysis
J Pharm Pharm Sci. 2024 Feb 16;27:12671. doi: 10.3389/jpps.2024.12671. eCollection 2024.ABSTRACTThis editorial explores how artificial intelligence (AI) is revolutionizing the science of pharmacokinetics (PK). It discusses the challenges of conventional PK analysis and how AI has transformed this area. It highlights the promise of artificial intelligence (AI) in predicting pharmacokinetic profiles from chemical structures and its application in several aspects of pharmacology, including dosage customization and drug interactions. Additionally, it emphasizes how important ethical issues and openness are to AI applications, ...
Source: J Pharm Pharm Sci - March 4, 2024 Category: Drugs & Pharmacology Authors: Ali Ghayoor Hamed Gilzad Kohan Source Type: research

Revolutionizing pharmacokinetics: the dawn of AI-powered analysis
J Pharm Pharm Sci. 2024 Feb 16;27:12671. doi: 10.3389/jpps.2024.12671. eCollection 2024.ABSTRACTThis editorial explores how artificial intelligence (AI) is revolutionizing the science of pharmacokinetics (PK). It discusses the challenges of conventional PK analysis and how AI has transformed this area. It highlights the promise of artificial intelligence (AI) in predicting pharmacokinetic profiles from chemical structures and its application in several aspects of pharmacology, including dosage customization and drug interactions. Additionally, it emphasizes how important ethical issues and openness are to AI applications, ...
Source: J Pharm Pharm Sci - March 4, 2024 Category: Drugs & Pharmacology Authors: Ali Ghayoor Hamed Gilzad Kohan Source Type: research

Revolutionizing pharmacokinetics: the dawn of AI-powered analysis
J Pharm Pharm Sci. 2024 Feb 16;27:12671. doi: 10.3389/jpps.2024.12671. eCollection 2024.ABSTRACTThis editorial explores how artificial intelligence (AI) is revolutionizing the science of pharmacokinetics (PK). It discusses the challenges of conventional PK analysis and how AI has transformed this area. It highlights the promise of artificial intelligence (AI) in predicting pharmacokinetic profiles from chemical structures and its application in several aspects of pharmacology, including dosage customization and drug interactions. Additionally, it emphasizes how important ethical issues and openness are to AI applications, ...
Source: J Pharm Pharm Sci - March 4, 2024 Category: Drugs & Pharmacology Authors: Ali Ghayoor Hamed Gilzad Kohan Source Type: research

What a pain in the … back: a review of current treatment options with a focus on naproxen sodium
J Pharm Pharm Sci. 2024 Feb 7;27:12384. doi: 10.3389/jpps.2024.12384. eCollection 2024.ABSTRACTNon-specific low back pain (LBP) represents a challenging and prevalent condition that is one of the most common symptoms leading to primary care physician visits. While established guidelines recommend prioritizing non-pharmacological approaches as the primary course of action, pharmacological treatments are advised when non-pharmacological approaches are ineffective or based on patient preference. These guidelines recommend non-steroidal anti-inflammatory drugs (NSAIDs) or skeletal muscle relaxers (SMRs) as the first-line pharm...
Source: J Pharm Pharm Sci - February 22, 2024 Category: Drugs & Pharmacology Authors: Steven M Weisman Giovanni Ciavarra Grant Cooper Source Type: research

What a pain in the … back: a review of current treatment options with a focus on naproxen sodium
J Pharm Pharm Sci. 2024 Feb 7;27:12384. doi: 10.3389/jpps.2024.12384. eCollection 2024.ABSTRACTNon-specific low back pain (LBP) represents a challenging and prevalent condition that is one of the most common symptoms leading to primary care physician visits. While established guidelines recommend prioritizing non-pharmacological approaches as the primary course of action, pharmacological treatments are advised when non-pharmacological approaches are ineffective or based on patient preference. These guidelines recommend non-steroidal anti-inflammatory drugs (NSAIDs) or skeletal muscle relaxers (SMRs) as the first-line pharm...
Source: J Pharm Pharm Sci - February 22, 2024 Category: Drugs & Pharmacology Authors: Steven M Weisman Giovanni Ciavarra Grant Cooper Source Type: research

What a pain in the … back: a review of current treatment options with a focus on naproxen sodium
J Pharm Pharm Sci. 2024 Feb 7;27:12384. doi: 10.3389/jpps.2024.12384. eCollection 2024.ABSTRACTNon-specific low back pain (LBP) represents a challenging and prevalent condition that is one of the most common symptoms leading to primary care physician visits. While established guidelines recommend prioritizing non-pharmacological approaches as the primary course of action, pharmacological treatments are advised when non-pharmacological approaches are ineffective or based on patient preference. These guidelines recommend non-steroidal anti-inflammatory drugs (NSAIDs) or skeletal muscle relaxers (SMRs) as the first-line pharm...
Source: J Pharm Pharm Sci - February 22, 2024 Category: Drugs & Pharmacology Authors: Steven M Weisman Giovanni Ciavarra Grant Cooper Source Type: research

What a pain in the … back: a review of current treatment options with a focus on naproxen sodium
J Pharm Pharm Sci. 2024 Feb 7;27:12384. doi: 10.3389/jpps.2024.12384. eCollection 2024.ABSTRACTNon-specific low back pain (LBP) represents a challenging and prevalent condition that is one of the most common symptoms leading to primary care physician visits. While established guidelines recommend prioritizing non-pharmacological approaches as the primary course of action, pharmacological treatments are advised when non-pharmacological approaches are ineffective or based on patient preference. These guidelines recommend non-steroidal anti-inflammatory drugs (NSAIDs) or skeletal muscle relaxers (SMRs) as the first-line pharm...
Source: J Pharm Pharm Sci - February 22, 2024 Category: Drugs & Pharmacology Authors: Steven M Weisman Giovanni Ciavarra Grant Cooper Source Type: research

What a pain in the … back: a review of current treatment options with a focus on naproxen sodium
J Pharm Pharm Sci. 2024 Feb 7;27:12384. doi: 10.3389/jpps.2024.12384. eCollection 2024.ABSTRACTNon-specific low back pain (LBP) represents a challenging and prevalent condition that is one of the most common symptoms leading to primary care physician visits. While established guidelines recommend prioritizing non-pharmacological approaches as the primary course of action, pharmacological treatments are advised when non-pharmacological approaches are ineffective or based on patient preference. These guidelines recommend non-steroidal anti-inflammatory drugs (NSAIDs) or skeletal muscle relaxers (SMRs) as the first-line pharm...
Source: J Pharm Pharm Sci - February 22, 2024 Category: Drugs & Pharmacology Authors: Steven M Weisman Giovanni Ciavarra Grant Cooper Source Type: research